| Page 2058 | Kisaco Research
 

Josep Samitier

Director
Institute for Bioengineering of Catalonia

Josep Samitier

Director
Institute for Bioengineering of Catalonia

Josep Samitier

Director
Institute for Bioengineering of Catalonia
 

Philip Hewitt

Global Head of early Non Clinical Safety (Liver and Kidney)
Merck KGaA

Philip Hewitt

Global Head of early Non Clinical Safety (Liver and Kidney)
Merck KGaA

Philip Hewitt

Global Head of early Non Clinical Safety (Liver and Kidney)
Merck KGaA
 

Magnus Ingelman-Sundberg

Karolinska Institutet

Magnus Ingelman-Sundberg

Karolinska Institutet

Magnus Ingelman-Sundberg

Karolinska Institutet
 

Professor Paul Gatenholm

Chemistry and Chemical Engineering
Biopolymer Technology

Professor Paul Gatenholm

Chemistry and Chemical Engineering
Biopolymer Technology

Professor Paul Gatenholm

Chemistry and Chemical Engineering
Biopolymer Technology
 

Robert Vries

Managing Director
Hubrecht Organoid Technology

Robert Vries

Managing Director
Hubrecht Organoid Technology

Robert Vries

Managing Director
Hubrecht Organoid Technology
 

Tommy Andersson

Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit
AstraZeneca R&D Mölndal

Tommy Andersson

Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit
AstraZeneca R&D Mölndal

Tommy Andersson

Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit
AstraZeneca R&D Mölndal
 

Heinz-Ruffner

Project Leader
Novartis Institutes for Biomedical Research

Heinz-Ruffner

Project Leader
Novartis Institutes for Biomedical Research

Heinz-Ruffner

Project Leader
Novartis Institutes for Biomedical Research
 

Gabor Forgacs

Scientific Founder and Chief Scientific Officer
Modern Meadow, Inc.

Gabor Forgacs

Scientific Founder and Chief Scientific Officer
Modern Meadow, Inc.

Gabor Forgacs

Scientific Founder and Chief Scientific Officer
Modern Meadow, Inc.
 

David H. Donabedian

Co-founder & CEO
Axial Biotherapeutics

David H. Donabedian, Ph.D., will serve as Chief Executive Officer of Axial and will also serve on its Board.  Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund.

Read full bio

David H. Donabedian

Co-founder & CEO
Axial Biotherapeutics

David H. Donabedian

Co-founder & CEO
Axial Biotherapeutics

David H. Donabedian, Ph.D., will serve as Chief Executive Officer of Axial and will also serve on its Board.  Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund.

Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group.

He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.